Skip to main content

Want a detailed portfolio tracker?

Apellis Pharmaceuticals (APLS) P/E (2018 - 2026)

Apellis Pharmaceuticals (APLS) P/E from Jan 2, 2018 to May 14, 2026. The TTM Apellis Pharmaceuticals (APLS) P/E is 39.02. You can export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

P/E

Annual P/E change of Apellis Pharmaceuticals (APLS)

YearP/EChange
202639.02-73.31%
2025146.19-842.07%
2024-19.70+72.83%
2023-11.40+32.55%
2022-8.60+59.14%
2021-5.40-56.80%
2020-12.51+95.34%
2019-6.40+12.25%
2018-5.70N/A

Comparison Apellis Pharmaceuticals (APLS) P/E with competitors

Apellis Pharmaceuticals (APLS) P/E is 39.02.

TickerNameP/EUpside
SPRCSciSparc Ltd0.00-100.00%
NBYStablecoin Development Corp0.00-99.99%
ENLVEnlivex Ltd0.07-99.81%
FGENFibroGen Inc0.24-99.38%
CHRSCoherus Biosciences Inc0.85-97.83%
FBIOFortress Biotech Inc0.95-97.57%
ORMPOramed Pharmaceuticals Inc1.50-96.15%
AGENAgenus Inc3.01-92.29%
INVAInnoviva Inc3.15-91.92%
VXRTVaxart Inc3.55-90.90%
CRMDCorMedix Inc3.63-90.70%
CVACCureVac N.V.4.45-88.61%
GLPGGalapagos NV4.86-87.55%
SRPTSarepta Therapeutics Inc4.88-87.49%
ABEOAbeona Therapeutics Inc5.39-86.19%
ABUSArbutus Biopharma Corp5.60-85.66%
ZVRAZevra Therapeutics Inc5.89-84.91%
SPROSpero Therapeutics Inc6.23-84.04%
CGENCompugen Ltd6.31-83.82%
RIGLRigel Pharmaceuticals6.87-82.39%
SLXNSilexion Therapeutics Corp7.30-81.30%
OMEROmeros Corporation9.26-76.27%
AUPHAurinia Pharmaceuticals Inc9.58-75.44%
PLXProtalix BioTherapeutics Inc10.89-72.09%
ACADAcadia Pharmaceuticals Inc11.73-69.94%
TBPHTheravance Biopharma Inc12.26-68.57%
ADMAAdma Biologics Inc12.42-68.17%
HRMYHarmony Biosciences Holdings Inc13.82-64.58%
SABSSAB Biotherapeutics Inc14.14-63.77%
NAGENiagen Bioscience Inc14.82-62.02%
INCYIncyte Corp15.82-59.45%
REGNRegeneron Pharmaceuticals Inc15.86-59.36%
PBYIPuma Biotechnology Inc17.32-55.62%
CPRXCatalyst Pharmaceuticals Inc17.44-55.31%
EXELExelixis Inc17.54-55.05%
TGTXTG Therapeutics Inc18.97-51.39%
MDXGMimedx Group Inc20.55-47.33%
XOMAXOMA Royalty Corp22.87-41.37%
ARGXArgen X SE24.30-37.73%
CTMXCytomX Therapeutics Inc24.82-36.39%
XOMAOXOMA Royalty Corp25.34-35.04%
HALOHalozyme Therapeutics Inc25.62-34.33%
XOMAPXOMA Royalty Corp25.67-34.21%
VRTXVertex Pharmaceuticals Inc27.99-28.25%
RPRXRoyalty Pharma plc - Class A28.69-26.48%
SLNOSoleno Therapeutics Inc29.02-25.64%
ASNDAscendis Pharma A/S30.09-22.89%
LGNDLigand Pharmaceuticals Inc - Class B37.91-2.83%
BMRNBiomarin Pharmaceutical Inc42.21+8.19%
KRYSKrystal Biotech Inc45.34+16.21%
ONCBeiGene Ltd69.54+78.23%
PHARPharming Group N.V.75.03+92.28%
TECHBio-Techne Corp101.96+161.31%
VCELVericel Corp109.92+181.72%
ALNYAlnylam Pharmaceuticals Inc117.96+202.34%
GMABGenmab140.29+259.55%
TLXTelix Pharmaceuticals Ltd162.15+315.59%
CORTCorcept Therapeutics Inc212.86+445.54%